CL2016001348A1 - Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras. - Google Patents

Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.

Info

Publication number
CL2016001348A1
CL2016001348A1 CL2016001348A CL2016001348A CL2016001348A1 CL 2016001348 A1 CL2016001348 A1 CL 2016001348A1 CL 2016001348 A CL2016001348 A CL 2016001348A CL 2016001348 A CL2016001348 A CL 2016001348A CL 2016001348 A1 CL2016001348 A1 CL 2016001348A1
Authority
CL
Chile
Prior art keywords
methyl
triazol
imidazol
benzo
phenyl
Prior art date
Application number
CL2016001348A
Other languages
English (en)
Inventor
Markus Gude
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T Williams
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2016001348A1 publication Critical patent/CL2016001348A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

FORMA CRISTALINA DEL COMPUESTO S)-(2-(6-CLORO-7-METIL-1H-BENZO[D]IMIDAZOL-2-IL)-2-METIL-PIRROLIDIN-1-IL)(5-METOXI-2-(2H-1,2,3-TRIAZOL-2-IL)FENIL)METANONA SUS SALES, ANTAGONISTA DEL RECEPTOR DE OREXINA; COMPOSICION FARMACEUTICA; Y SU USO PARA EL TRATAMIENTO O PRECENCIPN DE NUN AENFERMEDAD O TRASTORNO SELECCIONADO DEL GRUPO ENTRE TRASTORNOS EL SUEÑO, TRASTORNOS DE ANSIEDAD, DE ADICCION DE HUMOR, DEL APETITO Y DISFUNCIONES COGNITIVAS.
CL2016001348A 2013-12-03 2016-06-02 Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras. CL2016001348A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2013060595 2013-12-03

Publications (1)

Publication Number Publication Date
CL2016001348A1 true CL2016001348A1 (es) 2016-11-25

Family

ID=52282787

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001348A CL2016001348A1 (es) 2013-12-03 2016-06-02 Forma cristalina de clorhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que la comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.

Country Status (31)

Country Link
US (2) US9790208B2 (es)
EP (1) EP3077390B1 (es)
JP (1) JP6091716B2 (es)
KR (1) KR101839716B1 (es)
CN (1) CN105793258B (es)
AU (1) AU2014358743B2 (es)
CA (1) CA2929720C (es)
CL (1) CL2016001348A1 (es)
CY (1) CY1119687T1 (es)
DK (1) DK3077390T3 (es)
EA (1) EA030109B1 (es)
ES (1) ES2651508T3 (es)
HR (1) HRP20171772T1 (es)
HU (1) HUE034656T2 (es)
IL (1) IL245922B (es)
LT (1) LT3077390T (es)
MA (1) MA39164B1 (es)
MX (1) MX362701B (es)
MY (1) MY176244A (es)
NO (1) NO3077390T3 (es)
NZ (1) NZ721493A (es)
PH (1) PH12016500989B1 (es)
PL (1) PL3077390T3 (es)
PT (1) PT3077390T (es)
SA (1) SA516371248B1 (es)
SG (1) SG11201604541WA (es)
SI (1) SI3077390T1 (es)
TW (1) TWI636982B (es)
UA (1) UA119151C2 (es)
WO (1) WO2015083071A1 (es)
ZA (1) ZA201604501B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
JP6496733B2 (ja) * 2013-12-03 2019-04-03 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ （ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
KR102582197B1 (ko) 2017-05-03 2023-09-22 이도르시아 파마슈티컬스 리미티드 2-([1,2,3]트리아졸-2-일)-벤조산 유도체의 제조
EP4138822A1 (en) 2020-04-19 2023-03-01 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
CN117736193B (zh) * 2023-12-19 2024-07-23 南京知和医药科技有限公司 一种氘代稠环化合物及其制备方法与用途
ES3038762A1 (es) 2024-04-12 2025-10-14 Moehs Iberica Sl Procedimiento de síntesis de ácido 5-metoxi-2-(2H-1,2,3-triazol-2yl)benzoico, sal sódica de dicho ácido como intermedio de síntesis y uso del ácido o de su sal en la preparación de daridorexant y ciertos intermedios en la síntesis del mismo
WO2025253419A1 (en) * 2024-06-06 2025-12-11 Msn Laboratories Private Limited, R&D Center Solid state forms of (s)-(2-(5-chloro-4-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride and processes for preparation thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
CA2425185A1 (en) 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
CZ20032990A3 (cs) 2001-05-05 2004-04-14 Smithkline Beecham P. L. C. N-aroylové cyklické aminy
WO2003002561A1 (en) * 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
JP4094050B2 (ja) 2004-03-01 2008-06-04 アクテリオン ファーマシューティカルズ リミテッド 置換１，２，３，４−テトラヒドロイソキノリン誘導体
EP1998774A1 (en) 2006-03-15 2008-12-10 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinoline derivatives to enhance memory function
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
CA2659299A1 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
ES2351079T3 (es) 2007-05-14 2011-01-31 Actelion Pharmaceuticals Ltd. Derivados de 2-ciclopropil-tiazol.
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
TW200911242A (en) 2007-07-03 2009-03-16 Glaxo Group Ltd Novel compounds
JP2010531871A (ja) 2007-07-03 2010-09-30 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．３．０］オクタン化合物
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
KR20100046047A (ko) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
EP2185512B1 (en) 2007-07-27 2010-12-29 Actelion Pharmaceuticals Ltd. Trans-3-aza-bicyclo[3.1.0]hexane derivatives
CA2699328A1 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
BRPI0908096A2 (pt) 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CA2729985A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
EP2358712A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
EP2358713A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
CA2745433A1 (en) 2008-12-02 2010-06-10 Glaxo Group Ltd. N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
GB0823467D0 (en) * 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US20120040991A1 (en) 2009-04-24 2012-02-16 Glaxo Group Limited 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
TW201209037A (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
WO2012063207A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
DK2776430T3 (en) 2011-11-08 2016-05-09 Actelion Pharmaceuticals Ltd 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists
KR102181318B1 (ko) * 2012-04-17 2020-11-20 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 화합물 및 방법
TWI570120B (zh) * 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
AU2013328301A1 (en) * 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
JP6496733B2 (ja) 2013-12-03 2019-04-03 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ （ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도

Also Published As

Publication number Publication date
UA119151C2 (uk) 2019-05-10
MA39164B1 (fr) 2019-03-29
US10023560B2 (en) 2018-07-17
MX2016007216A (es) 2016-09-07
JP2016539135A (ja) 2016-12-15
EA201600436A1 (ru) 2016-11-30
ZA201604501B (en) 2018-12-19
PH12016500989A1 (en) 2016-06-20
SA516371248B1 (ar) 2018-03-19
AU2014358743B2 (en) 2018-11-29
CN105793258B (zh) 2018-12-28
SG11201604541WA (en) 2016-07-28
IL245922A0 (en) 2016-08-02
KR20160093683A (ko) 2016-08-08
US20160355506A1 (en) 2016-12-08
BR112016012625A2 (es) 2017-08-22
PL3077390T3 (pl) 2018-02-28
EP3077390B1 (en) 2017-09-13
AU2014358743A1 (en) 2016-07-14
LT3077390T (lt) 2017-11-27
NZ721493A (en) 2021-12-24
PT3077390T (pt) 2017-12-15
SI3077390T1 (sl) 2017-12-29
HK1225736B (en) 2017-09-15
TWI636982B (zh) 2018-10-01
KR101839716B1 (ko) 2018-03-16
WO2015083071A1 (en) 2015-06-11
CN105793258A (zh) 2016-07-20
US20180002317A1 (en) 2018-01-04
ES2651508T3 (es) 2018-01-26
MY176244A (en) 2020-07-24
BR112016012625A8 (pt) 2017-12-26
MX362701B (es) 2019-02-01
DK3077390T3 (da) 2017-11-06
IL245922B (en) 2019-10-31
HRP20171772T1 (hr) 2017-12-29
HUE034656T2 (hu) 2018-02-28
CY1119687T1 (el) 2018-04-04
EP3077390A1 (en) 2016-10-12
US9790208B2 (en) 2017-10-17
EA030109B1 (ru) 2018-06-29
JP6091716B2 (ja) 2017-03-08
PH12016500989B1 (en) 2019-11-13
CA2929720C (en) 2019-06-18
MA39164A1 (fr) 2017-08-31
TW201605839A (zh) 2016-02-16
NO3077390T3 (es) 2018-02-10
CA2929720A1 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
CU20160149A7 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
CL2014000659A1 (es) Compuestos derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida, antagonistas del receptor de orexina; composicion farmaceutica; y su uso para la prevencion o el tratamiento de una enfermedad seleccionada del grupo que consiste en trastornos de ansiedad, adiccion, animicos y del apetito.
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CL2016001342A1 (es) Formas cristalinas hemihidrato y anhidrato de (s)-(2-(6-cloro-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona; composición farmacéutica que las comprende; y su uso para el tratamiento o prevención de trastornos del sueño, tales como disomnias, parasomnias, entre otras.
MX2017014375A (es) Moduladores del ccr2.
CL2008001658A1 (es) Composicion farmaceutica que comprende mesilato de imatinib amorfo y un principio de formulacion que estabiliza la forma amorfa; y su uso para tratar leucemia mieloide cronica avanzada y recientemente diagnosticada, leucemia mielomonocitica cronica, glioblastoma multiforme, entre otras.
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
PA8795701A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
CL2013003686A1 (es) Compuestos derivados de ergolina, antagonista del receptor de 5-ht1d; útiles para el tratamiento de la migraña.
EA201600436A1 (ru) Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CL2014002847A1 (es) Compuestos triazolo derivados, inhibidores de pde10; procedimiento de preparacion; uso para el tratamiento y/o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, adicciona a drogas, enfermedad de parkinson, entre otras.
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
LT3044223T (lt) 2,3-dihidro-1h-inden-1-ono dariniai, kaip su retinoine rūgštimi susijusio orfaninio receptoriaus gama (ror-gama) antagonistai, skirti išsėtinės sklerozės gydymui
UY33722A (es) Oxazolidinonas como moduladores de mglur5
CL2015003037A1 (es) Derivados de triazina
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
UY34734A (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer.